Ofatumumab

Drug Profile

Ofatumumab

Alternative Names: Anti-CD20 monoclonal antibody - Novartis; Arzerra; GSK-1841157; HuMax CD20; OMB-157

Latest Information Update: 11 Jul 2017

Price : $50

At a glance

  • Originator Genmab
  • Developer Genmab; GlaxoSmithKline; Mundipharma International; National Cancer Centre (Singapore); Novartis; Roswell Park Cancer Institute; University Health Network
  • Class Antineoplastics; Antirheumatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action CD20 antigen inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic lymphocytic leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic lymphocytic leukaemia
  • Phase III Diffuse large B cell lymphoma; Follicular lymphoma; Multiple sclerosis
  • Phase II Acute lymphoblastic leukaemia; MALT lymphoma
  • Suspended Neuromyelitis optica
  • Discontinued Pemphigus vulgaris; Rheumatoid arthritis; Waldenstrom's macroglobulinaemia

Most Recent Events

  • 30 Apr 2017 Novartis completes a phase III trial in Chronic lymphocytic leukaemia (Second-line therapy) in European Union, Israel, Russia, Singapore and Ukraine (IV) (NCT01313689)
  • 22 Apr 2017 Pharmacodynamics data from a preclinical study in Multiple sclerosis presented at the 69th Annual Meeting of the American Academy of Neurology (AAN-2017)
  • 05 Apr 2017 Novartis plans regulatory filings in relapsing Multiple sclerosis in 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top